Analysis of sPD-1 and sPD-L1 levels in renal cell carcinoma (RCC), a tumor responsive to checkpoint inhibitors, revealed no significant differences in sPD-1 levels between healthy donors and RCC patients, while sPD-L1 levels were significantly elevated. This evidence concerns the gene HOXD13 and renal cell adenocarcinoma.